TransMedics Group Inc. (TMDX)

TransMedics (TMDX) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, TMDX broke out above the 50-day moving average, suggesting...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

TransMedics stock jumps 10.5% as Q2 EPS beats by 91.7%, revenue rises 37.7%, and operating margin expands 1230 basis points.

TransMedics delivered strong Q2 results, with revenue growth remaining robust and margins improving sharply. While there are concerns around the regulatory environment, competition, and seasonality, T...

Shares of leading organ transplant technology company TransMedics (TMDX 12.66%) rose 15% as of noon ET on Thursday, according to data provided by S&P Global Market Intelligence.

TransMedics Group (TMDX 2.92%), a leader in organ transplant technology, released its second quarter 2025 earnings on July 30, 2025. The company topped Wall Street expectations, posting GAAP revenue o...

TransMedics Group, Inc. (NASDAQ:TMDX ) Q2 2025 Earnings Conference Call July 30, 2025 4:30 PM ET Company Participants Waleed Hassanein - Founder, President, CEO & Director Gerardo Hernandez - CFO & Tr...

The headline numbers for TransMedics (TMDX) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estim...

TransMedics (TMDX) came out with quarterly earnings of $0.92 per share, beating the Zacks Consensus Estimate of $0.48 per share. This compares to earnings of $0.35 per share a year ago.